Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer

Anticancer Research

Volumn 32, Issue 7, 2012, Pages 2391-2398

  Spencer, Shawn ^a   Marini, Bernard L ^b   Figg, William D ^c  

^a SAIC FREDERICK INC   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bone metastases; Pharmacotherapy; Prostate cancer (PCa); Review; Skeletal related events (SRE)

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; ATRASENTAN; BALICATIB; BISPHOSPHONIC ACID DERIVATIVE; BOSUTINIB; CABOZANTINIB; CATHEPSIN K; DASATINIB; DENOSUMAB; DOCETAXEL; DOXORUBICIN; ENDOTHELIN; GEMCITABINE; MATRIX METALLOPROTEINASE; ODANACATIB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; RADIOPHARMACEUTICAL AGENT; RADIUM 223; REBIMASTAT; SAMARIUM 153; SARACATINIB; STRONTIUM 89; UNCLASSIFIED DRUG; ZIBOTENTAN; ZOLEDRONIC ACID;

ANALGESIA; ARTHRALGIA; BONE DISEASE; BONE METASTASIS; BONE PAIN; BONE TURNOVER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PAIN; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; HUMAN; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MYALGIA; NAUSEA; NONHUMAN; NOSE CONGESTION; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKELETAL RELATED EVENT; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; DIPHOSPHONATES; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; OSTEOBLASTS; PROSTATIC NEOPLASMS;

EID: 84865677083     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Howlader N, Noone A, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse S, Kosary C, Ruhl J and Tatalovich Z: SEER Cancer Statistics Review, 1975-2008 [based on November 2010 SEER data submission, posted to the SEER website 2011]. Bethesda, MD: National Cancer Institute, 2011.
2. Smith MR, Cook R, Lee KA and Nelson JB: Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer 117: 2077-2085, 2011.
3. Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, Cook R and Higano CS: Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23: 2918-2925, 2005. (Pubitemid 46224110)
4. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC and Mihatsch MJ: Metastatic patterns of prostate cancer: An autopsy study of 1,589 patients. Hum Pathol 31: 578-583, 2000. (Pubitemid 30323983)
5. Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP and Sorensen HT: Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 184: 162-167, 2010.
6. Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M and Halabi S: The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 46: 517-525, 2010.
7. Thobe MN, Clark RJ, Bainer RO, Prasad SM and Rinker-Schaeffer CW: From prostate to bone: Key players in prostate cancer bone metastasis. Cancers (Basel) 3: 478-493, 2011.
8. Msaouel P, Pissimissis N, Halapas A and Koutsilieris M: Mechanisms of bone metastasis in prostate cancer: clinical implications. Best Pract Res Clin Endocrinol Metab 22: 341-355, 2008. (Pubitemid 351611957)
9. Clarke NW, Hart CA and Brown MD: Molecular mechanisms of metastasis in prostate cancer. Asian J Androl 11: 57-67, 2009.
10. Jin JK, Dayyani F and Gallick GE: Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer 128: 2545-2561, 2011.
11. Ye L, Kynaston HG and Jiang WG: Bone metastasis in prostate cancer: molecular and cellular mechanisms (review). Int J Mol Med 20: 103-111, 2007.
12. Arya M, Bott SR, Shergill IS, Ahmed HU, Williamson M and Patel HR: The metastatic cascade in prostate cancer. Surg Oncol 15: 117-128, 2006. (Pubitemid 46241866)
13. Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA and Schulman KA: The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16: 579-584, 2005. (Pubitemid 40613323)
14. Mohler J, Bahnson RR, Boston B, Busby JE, D'Amico A, Eastham JA, Enke CA, George D, Horwitz EM, Huben RP, Kantoff P, Kawachi M, Kuettel M, Lange PH, Macvicar G, Plimack ER, Pow-Sang JM, Roach M, 3rd, Rohren E, Roth BJ, Shrieve DC, Smith MR, Srinivas S, Twardowski P and Walsh PC: NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 8: 162-200, 2010.
15. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F and Heidenreich A: EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59: 572-583, 2011.
16. Green JR: Bisphosphonates: preclinical review. Oncologist 9(Suppl 4): 3-13, 2004.
17. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V and Green JR: Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302: 1055-1061, 2002. (Pubitemid 34920226)
18. Santini D, Vincenzi B, Avvisati G, Dicuonzo G, Battistoni F, Gavasci M, Salerno A, Denaro V and Tonini G: Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 8: 1080-1084, 2002. (Pubitemid 34517643)
19. Castella B, Riganti C, Fiore F, Pantaleoni F, Canepari ME, Peola S, Foglietta M, Palumbo A, Bosia A, Coscia M, Boccadoro M and Massaia M: Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between V&gamma9Vδ2 T cells, αβ; CD8+ T cells, regulatory T cells, and dendritic cells. J Immunol 187: 1578-1590, 2011.
20. Dumon JC, Journe F, Kheddoumi N, Lagneaux L and Body JJ: Cytostatic and apoptotic effects of bisphosphonates on prostate cancer cells. Eur Urol 45: 521-528; discussion 528-529, 2004.
21. Nakajima H, Magae J, Tsuruga M, Sakaguchi K, Fujiwara I, Mizuta M, Sawai K, Yamagishi H and Mizuta N: Induction of mitochondria-dependent apoptosis through the inhibition of mevalonate pathway in human breast cancer cells by YM529, a new third generation bisphosphonate. Cancer Lett 253: 89-96, 2007. (Pubitemid 46874729)
22. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA and Chen B: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94: 1458-1468, 2002.
23. El-Mabhouh AA, Nation PN, Abele JT, Riauka T, Postema E, McEwan AJ and Mercer JR: A conjugate of gemcitabine with bisphosphonate (Gem/BP) shows potential as a targeted bone-specific therapeutic agent in an animal model of human breast cancer bone metastases. Oncol Res 19: 287-295, 2011.
24. Nakatake H, Ekimoto H, Aso M, Ogawa A, Yamaguchi A and Suemune H: Dialkyl bis phosphonate platinum(II) complex as a potential drug for metastatic bone tumor. Chem Pharm Bull (Tokyo) 59: 710-713, 2011.
25. Schott H, Goltz D, Schott TC, Jauch C and Schwendener RA: N-[Alkyl-(hydroxyphosphono)phosphonate]-cytidine-new drugs covalently linking antimetabolites (5-FdU, araU or AZT) with bone-targeting bisphosphonates (alendronate or pamidronate). Bioorg Med Chem 19: 3520-3526, 2011.
26. Salerno M, Cenni E, Fotia C, Avnet S, Granchi D, Castelli F, Micieli D, Pignatello R, Capulli M, Rucci N, Angelucci A, Del Fattore A, Teti A, Zini N, Giunti A and Baldini N: Bone-targeted doxorubicin-loaded nanoparticles as a tool for the treatment of skeletal metastases. Curr Cancer Drug Targets 10: 649-659, 2010.
27. Castellano D, Sepulveda JM, Garcia-Escobar I, Rodriguez- Antolin A, Sundlov A and Cortes-Funes H: The role of RANK-ligand inhibition in cancer: the story of denosumab. Oncologist 16: 136-145, 2011.
28. Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R and Goessl C: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 377: 813-822, 2011.
29. Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A and Culver KW: Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J Manag Care Pharm 17: 621-643, 2011.
30. Sartor O: Denosumab in bone-metastatic prostate cancer: Known effects on skeletal-related events but unknown effects on quality of life. Asian J Androl 13: 612-613, 2011.
31. Hemingway F, Taylor R, Knowles HJ and Athanasou NA: RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II. Bone 48: 938-944, 2011.
32. Furlow B: US FDA Advisory Panel rejects early denosumab therapy. Lancet Oncol 13(3): 94, 2012.
33. Roque IFM, Martinez-Zapata MJ, Scott-Brown M and Alonso-Coello P: Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev: CD003347, 2011.
34. Buchali K, Correns HJ, Schuerer M, Schnorr D, Lips H and Sydow K: Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med 14: 349-351, 1988.
35. Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, Reed NS, Russell JM and Yardley J: A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 31: 33-40, 1994. (Pubitemid 24167588)
36. Porfiri E, Collins S, Barton D, Billingham L, McLaren D, Nixon G, Russell J, Parker C, Wylie J and James N: Initial feasibility and safety results from a phase II/III clinical trial to evaluate docetaxel (D) therapy in combination with zoledronic acid (ZA){±} strontium-89 (Sr89) in hormone-refractory prostate cancer patients: ISRCTN12808747. J Clin Oncol 28: 385s (abstract 4677), 2010.
37. Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Theodore C and Loriot Y: Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 27: 2429, 2009.
38. Morris M, Pandit-Taskar N, Stephenson R, Hong C, Slovin S, Rathkopf D, Solit D, Carrasquillo J, Larson S and Scher H: Phase I/II study of docetaxel and 153Sm for castrate metastatic prostate cancer (CMPC): summary of dose-escalation dohorts and first report on the expansion cohort. J Clin Oncol 27: 5057, 2009.
39. Lin J, Sinibaldi V, Carducci M, Denmeade S, Song D, Deweese T and Eisenberger M: Phase I trial with a combination of docetaxel and (153) Sm-lexidronam in patients with castration-resistant metastatic prostate cancer. Urol Oncol, 2009.
40. Tu SM, Mathew P, Wong FC, Jones D, Johnson MM and Logothetis CJ: Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J Clin Oncol 27: 3319-3324, 2009.
41. El-Mabhouh A and Mercer JR: 188Re-labeled bisphosphonates as potential bifunctional agents for therapy in patients with bone metastases. Appl Radiat Isot 62: 541-549, 2005. (Pubitemid 40215549)
42. Ogawa K, Kawashima H, Shiba K, Washiyama K, Yoshimoto M, Kiyono Y, Ueda M, Mori H and Saji H: Development of [(90)Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases. Nucl Med Biol 36: 129-135, 2009.
43. Torres Martin de Rosales R, Finucane C, Foster J, Mather SJ and Blower PJ: 188Re(CO)3-dipicolylamine-alendronate: A new bisphosphonate conjugate for the radiotherapy of bone metastases. Bioconjug Chem 21: 811-815, 2010.
44. Gauthier JY, Chauret N, Cromlish W, Desmarais S, Duong le T, Falgueyret JP, Kimmel DB, Lamontagne S, Leger S, LeRiche T, Li CS, Masse F, McKay DJ, Nicoll-Griffith DA, Oballa RM, Palmer JT, Percival MD, Riendeau D, Robichaud J, Rodan GA, Rodan SB, Seto C, Therien M, Truong VL, Venuti MC, Wesolowski G, Young RN, Zamboni R and Black WC: The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 18: 923-928, 2008.
45. Podgorski I, Linebaugh BE, Koblinski JE, Rudy DL, Herroon MK, Olive MB and Sloane BF: Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis. Am J Pathol 175: 1255-1269, 2009.
46. Runger TM, Adami S, Benhamou CL, Czerwinski E, Farrerons J, Kendler DL, Mindeholm L, Realdi G, Roux C and Smith V: Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. J Am Acad Dermatol, 2011.
47. Jensen AB, Wynne C, Ramirez G, He W, Song Y, Berd Y, Wang H, Mehta A and Lombardi A: The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer 10: 452-458, 2010.
48. Carducci MA and Jimeno A: Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 12: 6296s-6300s, 2006. (Pubitemid 44703806)
49. Yuyama H, Koakutsu A, Fujiyasu N, Fujimori A, Sato S, Shibasaki K, Tanaka S, Sudoh K, Sasamata M and Miyata K: Inhibitory effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice. J Cardiovasc Pharmacol 44(Suppl 1): S479-482, 2004. (Pubitemid 40039743)
50. Carducci MA, Nelson JB, Bowling MK, Rogers T, Eisenberger MA, Sinibaldi V, Donehower R, Leahy TL, Carr RA, Isaacson JD, Janus TJ, Andre A, Hosmane BS and Padley RJ: Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J Clin Oncol 20: 2171-2180, 2002. (Pubitemid 34408809)
51. Carducci MA, Padley RJ, Breul J, Vogelzang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Weinberg MA, Schmitt JL and Nelson JB: Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 21: 679-689, 2003. (Pubitemid 46621903)
52. Carducci MA, Saad F, Abrahamsson PA, Dearnaley DP, Schulman CC, North SA, Sleep DJ, Isaacson JD and Nelson JB: A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 110: 1959-1966, 2007. (Pubitemid 350036854)
53. Schelman WR, Liu G, Wilding G, Morris T, Phung D and Dreicer R: A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer. Invest New Drugs 29: 118-125, 2011.
54. Trump DL, Payne H, Miller K, de Bono JS, Stephenson J, 3rd, Burris HA, 3rd, Nathan F, Taboada M, Morris T and Hubner A: Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer. Prostate 71: 1264-1275, 2011.
55. James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D and Dawson NA: Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 55: 1112-1123, 2009.
56. James ND, Caty A, Payne H, Borre M, Zonnenberg BA, Beuzeboc P, McIntosh S, Morris T, Phung D and Dawson NA: Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. BJU Int 106: 966-973, 2010.
57. Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R and Cher ML: Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 94: 17-25, 2002. (Pubitemid 34082839)
58. Rizvi NA, Humphrey JS, Ness EA, Johnson MD, Gupta E, Williams K, Daly DJ, Sonnichsen D, Conway D, Marshall J and Hurwitz H: A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res 10: 1963-1970, 2004. (Pubitemid 38375554)
59. Lara PN Jr., Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH and Gandara DR: A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res 12: 1556-1563, 2006.
60. Pezaro C, Rosenthal MA, Gurney H, Davis ID, Underhill C, Boyer MJ, Kotasek D, Solomon B and Toner GC: An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. Am J Clin Oncol 32: 338-341, 2009.
61. Dror Michaelson M, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson SZ, Spicer B, Gurski C, Kantoff PW and Smith MR: Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 20: 913-920, 2009.
62. Whang YE, Armstrong AJ, Rathmell WK, Godley PA, Kim WY, Pruthi RS, Wallen EM, Crane JM, Moore DT, Grigson G, Morris K, Watkins CP and George DJ: A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer. Urol Oncol, 2011.
63. Dahut WL, Scripture C, Posadas E, Jain L, Gulley JL, Arlen PM, Wright JJ, Yu Y, Cao L, Steinberg SM, Aragon-Ching JB, Venitz J, Jones E, Chen CC and Figg WD: A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 14: 209-214, 2008. (Pubitemid 351377997)
64. Mathew P, Tannir N, Tu SM, Wen S, Guo CC, Marcott V, Bekele BN and Pagliaro L: Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib. Cancer Chemother Pharmacol 68: 889-896, 2011.
65. Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL and Corey E: Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer 101: 263-268, 2009.
66. Yu EY, Wilding G, Posadas E, Gross M, Culine S, Massard C, Morris MJ, Hudes G, Calabro F, Cheng S, Trudel GC, Paliwal P and Sternberg CN: Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 15: 7421-7428, 2009.
67. Araujo JC, Mathew P, Armstrong AJ, Braud EL, Posadas E, Lonberg M, Gallick GE, Trudel GC, Paliwal P, Agrawal S and Logothetis CJ: Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. Cancer 118: 63-71, 2012.
68. Hannon RA, Clack G, Rimmer M, Swaisland A, Lockton JA, Finkelman RD and Eastell R: Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. J Bone Miner Res 25: 463-471, 2010.
69. Rabbani SA, Valentino ML, Arakelian A, Ali S and Boschelli F: SKI-606 (bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis. Mol Cancer Ther 9: 1147-1157, 2010.
70. Campone M, Bondarenko I, Brincat S, Hotko Y, Munster P, Chmielowska E, Fumoleau P, Ward R, Bardy-Bouxin N and Leip E: Phase II study of single-agent bosutinib, a SRC/ABL tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Annals of Oncology, 2011.
71. Hussain A, Evans C, Hannon R, Lipton A, Dimairo M, Yu J, Zobel P, Torti F and Finkelman R: A phase II, randomized, open-label, pilot study to evaluate the safety and the effects on bone resorption of saracatinib (AZD0530) in patients with prostate cancer or breast cancer with metastatic bone disease. Bone 48: S17-S17, 2011.
72. Laino C: Prostate cancer: promising results with cabozantinib, abiraterone, and degarelix. Oncology Times UK 8: 9, 2011.
73. Tuma RS: Dual-Targeted Agent Cabozantinib Shows Early Activity in Common Solid Tumors & Bone Metastases. Oncology Times 33: 52, 2011.
74. Hussain M, Smith M, Sweeney C, Corn P, Elfiky A, Gordon M, Haas N, Harzstark A, Kurzrock R and Lara Jr P: Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase 2 randomized discontinuation trial. J Clin Oncol 29(Suppl): (Abstr 4516), 2011.
75. Nilsson S, Larsen RH, Fossa SD, Balteskard L, Borch KW, Westlin JE, Salberg G and Bruland OS: First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 11: 4451-4459, 2005. (Pubitemid 40834252)
76. Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennernas B, Petersson U, Johannessen DC, Sokal M, Pigott K, Yachnin J, Garkavij M, Strang P, Harmenberg J, Bolstad B and Bruland OS: Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebocontrolled phase II study. Lancet Oncol 8: 587-594, 2007. (Pubitemid 46995621)
77. Parker C, Heinrich D, O'Sullivan J, Fossa S, Chodacki A, Demkow T, Cross A, Bolstad B, Garcia-Vargas J and Sartor O: Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA). Eur J Cancer 47: 3, 2011.
78. Nilsson S, O'Bryan-Tear C, Bolstad B, Lokna A and Parker C: Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223. J Clin Oncol 29(Suppl): a4620, 2011.